Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer
In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline.
As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today?
The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks?
Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer
Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer
PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile
Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib
The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients.
On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication.
On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer.
Page 3 of 33
Results 21 - 30 of 330
Results 21 - 30 of 330